Indeed, DI-Leu16-IL-2, when given subcutaneously in a Phase 2 clinical trial, showed adverse events and an expansion of Tregs that could be detrimental to the anti-tumor activity of the drug (16). This evidence concerns the gene IL2 and neoplasm.